The critique discusses fifty eight peptides in different clinical phases, indicating a robust pipeline of peptide therapies targeting PPIs.These procedures open new avenues for remedies personalized to beat precise breast most cancers subtypes and glioblastoma by honing in on integrins, fibronectins, and matrix metalloproteinases.Peptides have weak